Skip to content

Public FDA record

Z-1733-2024: BioZorb Marker-BioZorb 3D Bioabsorbable Marker-Intended Use radiographic marking of sites in soft tissue.

Recall record Z-1733-2024 for Hologic, Inc. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1733-2024
Company in FDA record
Hologic, Inc
FDA classification date
May 3, 2024
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class I

Reason stated in the source

Safety Information: Complaints describe complications/adverse events that include pain, infection, rash, device migration, device erosion, seroma, discomfort, or other complications from feeling the device in the breast, and the need for additional medical treatment to remove the device

Source facts

Action
Hologic issued Medical Device Safety Notification on 3/13/24 via Certified Mail. Letter states reason for notification, health risk and action to take: This notification should be shared with all surgeons in your practice that have or will use the BioZorb Marker. Recommendations for Patients " If you experience any adverse events following the placement of your BioZorb Marker, please contact your health care provider. " Discuss the benefits and possible risks of implantable breast tissue markers for breast cancer procedures with your health care provider. " Report any problems or complications experienced following the placement of BioZorb Marker devices to Hologic at breasthealth.support@hologic.com and to the FDA s MedWatch Adverse Event Reporting program. Recommendations for Health Care Providers " Be aware of reports of serious adverse events following the placement of the BioZorb Marker devices in breast tissue. " Discuss the benefits and possible risks of BioZorb Marker devices with your patient. " Continue to monitor patients who have an implanted BioZorb Marker for signs of any adverse events. " BioZorb Marker and BioZorb LP Marker are not cleared to fill space in the tissue or to improve cosmetic outcomes after procedures. " Inform your patient which device you plan to use, if you plan to implant a marking device during breast conservation surgery. " Report any problems or complications experienced by patients following placement of the BioZorb Marker devices to Hologic. Complaints can be submitted to breasthealth.support@hologic.com and to the FDA s MedWatch Adverse Event Reporting program. If you have any questions about this communication, please contact breasthealth.support@hologic.com. ***Update 10/7/2024*** On 9/5/2024 6 consignees were notified who received product since the initial letter was sent. This notification should be shared with all surgeons in your practice that have or will use the BioZorb Marker. Recommendations for Patients: " If you
Initiated
2024-03-13
Root cause
Unknown/Undetermined by firm
Distribution
US Nationwide Distribution
Recall number
Z-1733-2024
Recall status
Open, Classified
CDRH record ID
207014
FDA classified
2024-05-03
Recall event number
94359

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗